X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $450.0 million
Deal Type: Acquisition November 24, 2021
Details:
The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s disease.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $450.0 million
Deal Type: Acquisition October 11, 2021
Details:
At week 12, participants treated with GOCOVRI reported statistically significant improvements in motor control for daily activities compared to placebo (least-squares mean changes from baseline of –3.4 points for GOCOVRI and –1.4 for placebo).
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopaminergic medications.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Osmolex ER
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Osmotica Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 05, 2021
Details:
Under the terms of the agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER for $7.5 million.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Osmolex ER
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Osmotica Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Agreement December 02, 2020
Details:
Adamas has proposed to include GOCOVRI as an appropriate therapy for the treatment of OFF episodes in PD patients receiving levodopa. The clinical evidence supporting GOCOVRI’s effect on OFF time was demonstrated in two large pivotal Phase 3 trials.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
